Journal
FUTURE ONCOLOGY
Volume 16, Issue 22, Pages 1597-+Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0332
Keywords
lung cancer; next-generation sequence; precision medicine; sampling; success rate
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [JP19K176974]
- Takeda Science Foundation
- KAKENHI
- Chugai Pharma
- Novartis
- Lilly
- Merck Serono
- MSD
- Boehringer Ingelheim
- Ono Pharmaceutical
- Bristol-Myers Squibb
- AstraZeneca
- Chugai
- Ono
- MSD KK
- Chugai Pharceutical Co. Ltd AstraZeneca KK Takeda Pharmaceutical Companey Limited
- Regeneron Pharmaceuticals, Inc.
- Merck Serono Co., Ltd
- Pfizer Japan Inc.
- Taiho Pharmaceutical Co., Ltd
- Nippon Boehringer lngelheim Co., Ltd
- Eli Lilly Japan K.K.
- Novartis Pharma KK
- AbbVie GK.
- Delta-Fly Pharma, Inc.
- Osaka Foundation for The Prevention of Cancer and Life-style related Diseases
Ask authors/readers for more resources
Aim: We aimed to improve the success rate of NGS (next-generation sequencing) analysis through improved strategies of lung cancer sampling. Materials & methods: The improvement strategies are as follows. Surgically resected specimens were preferentially submitted in cooperation with pathologists and surgeons. In bronchoscopic samples, the size of the sample collection device and the number of samples collected was increased. Results: The strategies increased the success rate of NGS analysis of DNA from 69.3 to 91.1%, and that of RNA from 64.6 to 90.0%. Discussion: The introduction of strategies aimed at improving the success of NGS analysis resulted in an improvement in the success rate and brought us closer to the delivery of effective precision medicine in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available